Deltec Asset Management LLC Boosts Stock Position in Boston Scientific Corporation $BSX

Deltec Asset Management LLC grew its position in Boston Scientific Corporation (NYSE:BSX) by 335.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 28,300 shares of the medical equipment provider’s stock after purchasing an additional 21,800 shares during the quarter. Deltec Asset Management LLC’s holdings in Boston Scientific were worth $3,040,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in BSX. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter worth $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter worth $27,000. Sound Income Strategies LLC lifted its holdings in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific in the 2nd quarter worth $37,000. Finally, Activest Wealth Management lifted its holdings in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 373 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BSX. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. BTIG Research restated a “buy” rating and set a $127.00 price objective on shares of Boston Scientific in a research note on Tuesday, September 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday. Finally, Robert W. Baird upped their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Buy” and an average target price of $118.38.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,214 shares of company stock valued at $13,048,957 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.5%

Boston Scientific stock opened at $97.55 on Wednesday. The stock has a 50-day moving average of $103.53 and a two-hundred day moving average of $102.13. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The stock has a market cap of $144.54 billion, a PE ratio of 58.07, a price-to-earnings-growth ratio of 2.34 and a beta of 0.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.